MDGL - CIK 0001157601
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported net income of -$288.28M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$288.28M | +38.1% |
| FY 2024 | -$465.89M | -24.7% |
| FY 2023 | -$373.63M | -26.5% |
| FY 2022 | -$295.25M | -22.1% |
| FY 2021 | -$241.85M | -19.6% |
| FY 2020 | -$202.24M | -140.9% |
| FY 2019 | -$83.95M | -155.9% |
| FY 2018 | -$32.81M | -5.3% |
| FY 2017 |
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported net income of -$288.28M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2016 and fiscal 2025, MADRIGAL PHARMACEUTICALS, INC.'s net income declined from -$26.39M to -$288.28M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$31.15M |
| -18.1% |
| FY 2016 | -$26.39M | - |